Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Mucocele

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    26 result(s) found for: Mucocele. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2007-001850-18 Sponsor Protocol Number: 2007SA02 Start Date*: 2007-07-04
    Sponsor Name:NHS Tayside
    Full Title: A randomised controlled study on the effects of Mitomycin C versus placebo in adult endoscopic dacrocystorhinostomy
    Medical condition: Watery or sticky eye due to blockage of tear ducts
    Disease: Version SOC Term Classification Code Term Level
    9.1 10023622 Lacrimal duct obstruction LLT
    9.1 10023623 Lacrimal duct obstruction (acquired) LLT
    9.1 10023634 Lacrimal mucocele LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-004848-23 Sponsor Protocol Number: 89/2006/O/Sper Start Date*: 2006-09-12
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: Sequential Oral Therapy (SOT trial) in elderly patients with metastatic breast cancer: a phase IV randomized trial
    Medical condition: breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006279 Breast neoplasm LLT
    Population Age: Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-007089-12 Sponsor Protocol Number: 2606 B Start Date*: 2007-02-07
    Sponsor Name:GOIM GRUPPO ONCOLOGICO MERIDIONALE
    Full Title: Liposomial pegylate doxorubicine and trasuzumab in the first line treatment of the metastatised Her2 positive breast cancer for senior women
    Medical condition: Metastased breast cancer, first line treatment, for women with age>70 years old,Her2 positive
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006279 Breast neoplasm LLT
    Population Age: Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-001456-36 Sponsor Protocol Number: EGF100151 Start Date*: 2004-09-06
    Sponsor Name:GLAXO SMITHKLINE
    Full Title: A phase III, randomized, open-label, multicenter study comparing GW572016 and Capecitabile (Xeloda) versus Capecitabile in women with refractory advanced or metastatic breast cancer.
    Medical condition: Solid tumor treatment
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006279 Breast neoplasm PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-003752-38 Sponsor Protocol Number: om 169 Start Date*: 2003-12-09
    Sponsor Name:OSPEDALE ONCOLOGICO DI BARI
    Full Title: A phase II study of Capecitabine in combination with oral vinorelbine in advanced Breast Cancer
    Medical condition: advancer breast carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006279 Breast neoplasm LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-009418-42 Sponsor Protocol Number: INT-07/09 Start Date*: 2009-05-19
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: Phase II study evaluating efficacy and tolerability of Sorafenib in the treatment of iatrogenic lymphedema occurring in breast cancer patients following surgical dissection of, and/or radiotherapy ...
    Medical condition: Breast cancer patients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006279 Breast neoplasm LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004018-42 Sponsor Protocol Number: FARM5K3MEE Start Date*: 2006-09-15
    Sponsor Name:UNIVERSITA' DEGLI STUDI DI NAPOLI FEDERICO II
    Full Title: A phase III study comparing anastrozole, letrozole and exemestane, upfront (for 5 years) or sequentially (for 3 years after 2 years of tamoxifen), as adjuvant treatment of postmenopausal patients ...
    Medical condition: adjuvant hormono-therapy in breast cancer patients
    Disease: Version SOC Term Classification Code Term Level
    6.1 10006279 PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-005106-79 Sponsor Protocol Number: ST1481-DM02-008 Start Date*: 2005-02-01
    Sponsor Name:Sigma Tau industrie Farmaceutiche Riunite Spa
    Full Title: Phase II study of gimatecan (ST 1481) as salvage treatment in patients with advanced breast cancer after anthracycline /taxanes-based chemotherapy regimen
    Medical condition: advanced breast cancer
    Disease: Version SOC Term Classification Code Term Level
    10006285 LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-005021-30 Sponsor Protocol Number: FARM5P8YFC Start Date*: 2007-10-31
    Sponsor Name:REGIONE LOMBARDIA - DIREZIONE GENERALE SANITA'
    Full Title: TOP TRIAL. A RANDOMISED PHASE III CLINICAL TRIAL OF TRASTUZUMAB (HERCEPTIN) OPTIMIZATION IN PATIENTS WITH LOCALLY ADVANCED AND/OR METASTATIC BREAST CANCER OVEREXPRESSING HER2 AFTER A FIRST LINE CHE...
    Medical condition: Women with locally advanced or metastatic breast cancer over expressing HER2 who have been previously treated with a first line chemotherapy plus trastuzumab.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006279 Breast neoplasm LLT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-003989-15 Sponsor Protocol Number: P03679 Start Date*: 2005-02-28
    Sponsor Name:SCHERING-PLOUGH
    Full Title: Pegylated Liposomal Doxorubicin (Caleyx) in combination with Herceptin and Taxotere as first-line chemotherapy in metastatic breast cancer patients: A 2 stage Phase II, open label, Multicenter study.
    Medical condition: First line chemiotherapy in metastatic brest cancer patients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006279 Breast neoplasm LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-003216-39 Sponsor Protocol Number: IEO674 Start Date*: 2018-12-20
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA
    Full Title: Clinical utility of a next generation sequencing-based “oncochip” for therapeutic decision in metastatic breast cancer. Study SHARP
    Medical condition: Metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10006285 Breast neoplasm NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-002152-16 Sponsor Protocol Number: IEO S295/206 Start Date*: 2007-07-18
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA
    Full Title: Phase II randomized study of intravenous bevacizumab with sequential versus concurrent oral vinorelbine plus capecitabine in patients with locally advanced or recurrent breast cancer with lymphangi...
    Medical condition: locally advanced or recurrent breast cancer with lymphangitic spread to the chest wall.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006279 Breast neoplasm LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005208-20 Sponsor Protocol Number: 2019DEPO-TRIGGER001 Start Date*: 2022-08-10
    Sponsor Name:Universitair Ziekenhuis Brussel
    Full Title: Depo-Trigger trial: GnRH agonist DEPOt TRIGGER for final oocyte maturation in breast cancer patients undergoing fertility preservation: a pilot study.
    Medical condition: Female patients with breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006279 Breast neoplasm PT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005914-16 Sponsor Protocol Number: 2019COIMBRA001 Start Date*: 2021-03-01
    Sponsor Name:Universitair Ziekenhuis Brussel
    Full Title: COmbining Interventions of fertility preservation to Mitigate fertility loss after BReAst cancer
    Medical condition: Female patients with breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006279 Breast neoplasm PT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-002643-89 Sponsor Protocol Number: PALO-05-02 Start Date*: 2005-12-14
    Sponsor Name:Helsinn Healthcare SA
    Full Title: Double-blind Study to Compare the Efficacy of Palonosetron with or without the use of Dexamethasone on Days 2 and 3, in the Prevention of Nausea and Vomiting Induced by Moderately Emetogenic Chemot...
    Medical condition: This is a non-inferiority study in chemotherapy-naïve female patients with breast cancer, age 18 years or older, who are scheduled to receive Moderately Emetogenic Chemotherapy (MEC).
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) ES (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-016846-16 Sponsor Protocol Number: OCTO-16 Start Date*: 2010-12-14
    Sponsor Name:University of Oxford
    Full Title: Phase II Clinical Trial of 6-Mercaptopurine(6MP)and low-dose Methotrexate In Patients With Known BRCA Defective Tumours.
    Medical condition: Advanced or metastatic breast or ovarian cancer.
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028985 Neoplasm breast LLT
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-000490-30 Sponsor Protocol Number: METTEN-01 Start Date*: 2011-06-21
    Sponsor Name:Institut Català d'Oncologia
    Full Title: Phase II randomised, open-label, multicentric clinical trial of neoadjuvant treatment comprising chemotherapy and trastuzumab with or without metformin, in women with HER2/ErbB2 positive primary br...
    Medical condition: Women with stage II-III, HER2/ErbB2-positive primary breast cancer elegible for neoadjuvant treatment.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006279 Breast neoplasm PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-007057-12 Sponsor Protocol Number: ML21846 Start Date*: 2009-04-06
    Sponsor Name:ROCHE
    Full Title: A Randomized open label study of the effect of first line combination treatment with Avastin (bevacizumab) plus paclitaxel and gemcitabine Compared With Avastin (bevacizumab) plus paclitaxel on...
    Medical condition: Metastatic breast cancer, HER2-negative patients who have not received prior chemotherapy for mBC
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006285 LLT
    9.1 10055113 LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-000441-19 Sponsor Protocol Number: H3E-EW-S098 Start Date*: Information not available in EudraCT
    Sponsor Name:Eli lilly and Company Limited
    Full Title: A randomised Phase II study of two chemotherapy regimens, Pemetrexed-Carboplatin, and Gemcitabine-vinorelbine, in Anthracycline and Taxane pretreated Advanced Breast cancer patients.
    Medical condition: advanced breast cancer
    Disease: Version SOC Term Classification Code Term Level
    8.0 10006285 LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-004624-36 Sponsor Protocol Number: A6181099 Start Date*: 2007-03-19
    Sponsor Name:Pfizer Inc - 235 East 42nd Street, New York, NY 10017
    Full Title: A RANDOMIZED, PHASE 3 STUDY OF SUNITINIB IN COMBINATION WITH CAPECITABINE COMPARED WITH CAPECITABINE IN PATIENTS WITH PREVIOUSLY TREATED BREAST CANCER
    Medical condition: Advanced breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) FR (Completed) DK (Completed) DE (Prematurely Ended) AT (Prematurely Ended) GR (Prematurely Ended) CZ (Prematurely Ended) IT (Prematurely Ended) IE (Prematurely Ended) GB (Prematurely Ended) NL (Completed) ES (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 15 08:15:39 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA